Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a note issued to investors on Saturday. The brokerage set a “sell” rating on the stock.

Syros Pharmaceuticals Trading Down 10.9 %

SYRS stock opened at $0.03 on Friday. The stock has a market capitalization of $727,147.20, a PE ratio of -0.01 and a beta of 1.31. The stock’s 50 day simple moving average is $0.14 and its 200 day simple moving average is $0.80. Syros Pharmaceuticals has a 12-month low of $0.02 and a 12-month high of $6.93.

Institutional Trading of Syros Pharmaceuticals

A hedge fund recently bought a new stake in Syros Pharmaceuticals stock. Two Sigma Securities LLC purchased a new stake in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 107,742 shares of the company’s stock, valued at approximately $25,000. Two Sigma Securities LLC owned 0.40% of Syros Pharmaceuticals at the end of the most recent reporting period. 91.47% of the stock is currently owned by institutional investors and hedge funds.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.